Analyst Reco. Biogen Inc. Xetra

Equities

Real-time Estimate Tradegate Other stock markets 14:27:11 22/05/2024 BST			5-day change	1st Jan Change
210.1 ^EUR	+0.48%		-2.47%	-10.78%

02:18pm	Biogen to Acquire Human Immunology Biosciences for up to $1.8 Billion	MT
01:37pm	Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal	RE

Argus Raises Biogen's Price Target to $250 From $240	05-15	MT
Redburn Atlantic Adjusts Price Target on Biogen to $235 From $275, Keeps Neutral Rating	05-08	MT
HSBC Adjusts Price Target on Biogen to $342 From $339, Maintains Buy Rating	05-03	MT
Guggenheim Adjusts Price Target on Biogen to $255 From $275	04-26	MT
Goldman Sachs Adjusts Biogen Price Target to $340 From $393	04-25	MT
Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305	04-25	MT
Barclays Adjusts Price Target on Biogen to $200 From $215	04-25	MT
HC Wainwright Adjusts Biogen's Price Target to $300 From $325	04-25	MT
Wedbush Adjusts Price Target on Biogen to $215 From $213	04-25	MT
Morgan Stanley Cuts Biogen's Price Target to $331 From $339	04-24	MT
Piper Sandler Raises Biogen's Price Target to $335 From $325	04-24	MT
RBC Lowers Biogen's Price Target to $317 From $326	04-24	MT
Needham Adjusts Price Target on Biogen to $294 From $300	04-19	MT
BMO Capital Adjusts Price Target on Biogen to $260 From $285, Outperform Rating Kept	04-19	MT
Oppenheimer Adjusts Biogen Price Target to $270 From $290	04-19	MT
UBS Adjusts Biogen's Price Target to $214 From $250, Maintains Neutral Rating	04-17	MT
Wedbush Cuts Biogen's Price Target to $213 From $245	04-17	MT
Argus Adjusts Biogen's Price Target to $240 From $315	04-15	MT
Goldman Sachs Cuts Biogen's Price Target to $393 From $400	04-15	MT
JPMorgan Cuts Biogen's Price Target to $240 From $270, Maintains Neutral Rating	04-11	MT

No results for this search